In light of the emerging role of incretin-based therapies in addressing obesity in a specific population, this systematic review and meta-analysis aimed to evaluate the effects of GLP-1RAs on weight changes and clinical and metabolic outcomes in individuals with psychiatric disorders and obesity/overweight. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.